Pharvaris NV (FRA:9EN) Preferred Dividends : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Pharvaris NV's preferred dividends for the three months ended in Sep. 2024 was €0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Pharvaris NV Preferred Dividends Historical Data

The historical data trend for Pharvaris NV's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Preferred Dividends Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Preferred Dividends

Get a 7-Day Free Trial

Pharvaris NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Pharvaris NV Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Pharvaris NV (FRA:9EN) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Pharvaris NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

PHVS:USA

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Pharvaris NV Headlines

No Headlines